The U.S. government’s Center for Medicare and Medicaid Services sees healthcare spending rising 6% annually through 2025, even allowing for increased use of generic drugs. Yet, 60% fewer drugs go off-patent in 2017 by value than in 2016. Panjiva data shows the imports of four key generic classes (statins, anticonvulsants, P-PIs and insulins) already fell 5% in January. That was led by a 33% drop in statin imports, led by older treatments like pravastatin and simvastatin.